Is tuberculin skin testing reliable during anti-tumor necrosis factor-alfa therapy? A case report and review of the literature

Journal of the American Academy of Dermatology

Volumn 65, Issue 1, 2011, Pages 195-197

  Haddican, Madelaine M ^a   Koo, John Y M ^b  

^a NEW YORK MEDICAL COLLEGE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

anti tumor necrosis factor alfa therapy; psoriasis; QuantiFeron TB Gold; tuberculin skin testing

Indexed keywords

ETANERCEPT;

ADULT; ANAMNESIS; ARTICLE; CASE REPORT; FALSE NEGATIVE RESULT; HUMAN; INTERFERON GAMMA RELEASE ASSAY; LATENT TUBERCULOSIS; MALE; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; QUANTIFERON TB GOLD TEST; THORAX RADIOGRAPHY; TUBERCULIN TEST;

EID: 79958803217     PISSN: 01909622     EISSN: 10976787     Source Type: Journal    
DOI: 10.1016/j.jaad.2009.12.025     Document Type: Review

References (13)

1. Koo J. Population-based epidemiologic study of psoriasis with emphasis on quality of life assessment. Dermatol Clin 1996;14:485-96. (Pubitemid 26249398)
2. Wallis RS, Broder MS, Wong JY, Hanson ME, Beenhouwer DO. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis 2004;38:1261-5. (Pubitemid 38608568)
3. Doherty SD, Van Voorhees A, Lebwohl MG, Korman NJ, Young MS, Hsu S, et al. National Psoriasis Foundation consensus statement on screening for latent tuberculosis infection in patients with psoriasis treated with systemic and biologic agents. J Am Acad Dermatol 2008;59:209-17.
4. Brown AJ, Lesher JL Jr. Anti-tumor necrosis factor therapy and interpreting tuberculin skin tests. J Am Acad Dermatol 2009;60:21-2.
5. Hernandez C, Cetner AS, Jordan JE, Puangsuvan SN, Robinson JK. Tuberculosis in the age of biologic therapy. J Am Acad Dermatol 2008;59:363-80.
6. Menter A, Gottlieb A, Feldman SR, Van Voorhees AS, Leonardi CL, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis, section 1: overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol 2008;58:826-50. (Pubitemid 351509656)
7. Bartalesi F, Vicidomini S, Goletti D, Fiorelli C, Fiori G, Melchiorre D, et al. QuantiFeron-TB-Gold and the TST are both useful for latent tuberculosis infection screening in autoimmune diseases. Eur Respir J 2009;33:586-93.
8. Chen DY, Shen GH, Hsieh TY, Hsieh CW, Lan JL. Effectiveness of the combination of a whole-blood interferon-gamma assay and the tuberculin skin test in detecting latent tuberculosis infection in rheumatoid arthritis patients receiving adalimumab therapy. Arthritis Rheum 2008;59:800-6.
9. American Thoracic Society. Targeted tuberculin testing and treatment of latent tuberculosis infection. MMWR Morb Mortal Wkly Rep 2000;49:1-51.
10. Centers for Disease Control and Prevention. Tuberculosis associated with blocking agents against tumor necrosis alpha-California, 2002-2003. MMWR Morb Mortal Wkly Rep 2004;53:683-6.
11. Mazureck GH, Jereb J, Lobue P, Iademarco MF, Metchock B, Vernon A. Guidelines for using QuantiFeron-TB Gold test for detecting Mycobacterium tuberculosis infection, United States. MMWR Morb Mortal Wkly Rep 2005;54:49-55.
12. National Collaborating Center for Chronic Conditions. Tuberculosis: clinical diagnosis and management of tuberculosis, and measures for its prevention and control. London: Royal College of Physicians; 2006.
13. Pai M, Zwerling A, Menzies D. Systematic review: T-cell-based assays for diagnosis of latent tuberculosis infection: an update. Ann Intern Med 2008;149:177-84.